NCT06753903 Role of Photon Counting CT in Detecting Liver Metastatis From Colorectal Cancer
| NCT ID | NCT06753903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-03-24 |
| Primary Completion | 2028-03-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-03-24 with a primary completion date of 2028-03-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colorectal cancer is the first leading cause of cancer death in men and second in women. Its incidence rates also increased by 1%-2% annually in young adults (ages \<55 years). The liver is the most common site of colorectal cancer metastasis, with approximately 25% 50% of patients developing liver metastases during the disease. Maximising resection of liver metastasis using all available techniques remains a key objective and provides the best chance of long-term survival and cure. For unresectable patients, optimal systemic and locoregional chemotherapeutic, biological and radiotherapeutic treatments improve survival, and may convert initially unresectable patients to operability. Computed Tomography is currently the modality of choice for patients staging and restaging for high spatial resolution providing accurate delineation of lesion, vascular structure and relation with surrounding structure. The portal venous phase (approximately 60-70 s after administration of contrast agent) is the most reliable phase for detection of liver metastasis with a detection rate of 85% with lower performance for lesion \<1 cm which are interpreted as too small to characterize. Compared to computed tomography, MRI has superior soft tissue contrast and the possibly of a multiparametric characterization of lesion thanks to the evaluation of diffusivity and the uptake of hepatospecific contrast media, resulting in higher accuracy also for lesion smaller than \< 10 mm. Photon-counting detector computed tomography (PCD-CT), used as standard clinical practice, by employing a reduced radiation dose, allows the acquisition of ultra-high resolution images (up to 169 microns) and spectral information, with a high detection rate of liver metastases and their characterization. Therefore, aim of the present study is to evaluate the value of PCD-CT in the detection of liver metastasis from colorectal cancer in comparison to MRI as reference standard.
Eligibility Criteria
Inclusion Criteria: * adult (\>18 years) * non- biopsy-proven colon/colorectal carcinoma * CT performed on a PCD-CT * MRI with multiparametric protocol and hepatospecific contrast media Exclusion Criteria: * pregnancy and breastfeeding * CT exam performed on a scan different from PCD-CT * absence of multiparametric MRI * MRI with non hepatospecific contrast agent * Absent informed consent signed
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06753903 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06753903 currently recruiting?
Yes, NCT06753903 is actively recruiting participants. Contact the research team at esposito.antonio@hsr.it for enrollment information.
Where is the NCT06753903 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06753903 clinical trial?
NCT06753903 is sponsored by IRCCS San Raffaele. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.